First, we have tested the effect of PhP072 against a range of KRas-dependent cancer cells including PANC-1 (human pancreatic cancer, KRasG12D), SW1990 (human pancreatic cancer, KRas-G12D), SW48-PAR (human colon cancer; parental cell line KRaswt), and SW48-G12D (human colon cancer; heterozygous knockin of the KRasG12D activating mutation) cancer cell lines. This evidence concerns the gene KRAS and familial pancreatic carcinoma.